Skip to main content

Table 1 Clinical characteristics of 181 patients with CRO infections

From: Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections

Characteristic Findings
Age (year), mean ± SD 0.39 ± 0.17
Male, n (%) 135 (76.2)
APACHE II score, mean ± SD 19.25 ± 6.11
Distribution of departments, n (%)
 Hematology department 111 (61.3)
 ICU 58 (32.0)
 Other departments 12 (6.6)
Comorbidities, n (%)
 Chronic heart failure 52 (28.7)
 Diabetes mellitus 45 (24.9)
 COPD 34 (18.8)
 Chronic kidney disease 31 (17.7)
 Immunosuppressive status 25 (13.8)
Complications, n (%)
 Shock 42 (23.2)
 MODS 40 (22.1)
 ARDS 27 (14.9)
Infection types, n (%)
 Pneumonia 104 (57.5)
 Bloodstream infection 36 (19.9)
 Intestinal infection 35 (19.3)
 Abdominal infection 9 (5.0)
 Other infections 40 (22.1)
Multiple site infections 64 (35.4)
Responsible pathogens, n (%)
 K.P 91 (50.3)
 P.A 58 (32.0)
 E. coli 16 (8.8)
 A.B 12 (6.6)
Multiple bacterial infections 50 (27.6)
Polymyxin B dose, mean ± SD 1.91 ± 0.33
Initial treatment, n (%) 70 (38.7)
Duration of polymyxin B treatment, days, median (IQR) 11 (6, 19)
Antibiotic combination, n (%) 167 (92.3)
Microbiological eradication, n (%) 76 (42.0)
  1. APACHE II: acute physiology and chronic health evaluation II; ICU: intensive care unit; MODS: multiple organ dysfunction syndrome; ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; K.P.: Klebsiella pneumonia; P.A.: Pseudomonas aeruginosa; E. coli: Escherichia coli; E.fm: Enterococcus faecium; A.B.: Acinetobacter baumannii